For My Eyes Only: How to Protect Digital Diaries of Reproductive Data in a World Without Roe
Carolyn Zaccaro In 2022, the Supreme Court overturned Roe v. Wade with its decision in Dobbs v. Jackson Women’s Health Organization, leaving many individuals anxious about the future of their privacy rights. With millions of people using period-tracking apps, there is a massive amount of sensitive data at stake, including data that criminal prosecutors could use to criminalize people for seeking or having an abortion. Some people are better protected because of their home state’s data privacy legislation, but most Americans are left with no data privacy law protecting their sensitive data. In an era of sophisticated tracking technology, the absence of comprehensive...
The Supreme Court’s Missed Opportunity to Save Genus Claims in Life Sciences Patents
Alexander Franzosa The life sciences industry is a vital sector of the American economy, and its success is reliant on the protection of patent holder rights. One common feature in life sciences patents is the genus claim, a claim type traditionally allowing the patent holder to claim a group of related species based on common functionality. A novel interpretation of “written description,” a required element for patent applications, has emerged in recent decisions by the Court of Appeals for the Federal Circuit. This new interpretation has caused concern among some members of the life sciences industry regarding the validity of...
Allergan’s Battle to Stay in Court: Does Inter Partes Review Violate the Constitution by Circumventing Courtroom Adjudication?
Ashley E. Petrarca Since its institution in 2011, inter partes review has caused considerable disruption in the intellectual property world, with some industry players questioning the process’ constitutionality. One of these players is Dublin-based pharmaceutical company Allergan, Inc., which asserts that it is unfair to force patent owners to defend their USPTO-granted patent rights before the Patent Trial and Appeal Board (“PTAB”), a non-Article III sanctioned forum. Central to this debate is the question of whether patents confer private or public rights. This article discusses both sides of the dialogue over inter partes review constitutionality, and postulates that the process...